Department of Clinical Sciences and Bioimaging, Institute of Advanced Biomedical Technologies (ITAB), University G. d' Annunzio, Chieti-Pescara, Italy.
Curr Pharm Des. 2010;16(6):631-40. doi: 10.2174/138161210790883859.
Osteoarthritis (OA) is very disabling condition in the elderly. The current therapeutic approaches (analgesics, NSAIDs, COX-2 inhibitors, steroids) do not delay the OA progression or reverse joint damage. Moreover, they may cause relevant systemic side effects. Hyaluronic acid (HA) is a physiologic component of the synovial fluid and is reduced in OA joints. Therefore, intra-articular injection of HA, due to its viscoelastic properties and protective effect on articular cartilage and soft tissue surfaces of joints, can restore the normal articular homoeostasis. These effects are evident when HA is properly administered into the articular space; therefore, the use of "image-guided" infiltration techniques is mandatory. Viscosupplementation (VS), with different HA preparations (Low and High molecular weight), can be considered when the patient has not found pain relief from other therapies or is intolerant to analgesics or NSAIDs. A 3-5 doses regimen is usually recommended with 1 week interval between each injection. Several studies have shown the efficacy of HA for the treatment of knee OA, with positive effects on pain, articular function (Western Ontario and Mc Master Universities Osteoarthritis Index [WOMAC], Lequesne Index [LI], Range of Motion [ROM]), subjective global assessment and reduction in NSAIDs consumption. In general, the benefit is evident within 3 months and persists in the following 6-12 months. Encouraging but inconclusive results have also been observed for the treatment of shoulder, carpo-metacarpal, hip and ankle OA. However there is the need of better designed studies to prove the effectiveness of these medications, in order to rule out a placebo effect. The therapy is well tolerated with absence of systemic side effects and only with limited local discomfort.
骨关节炎(OA)是老年人非常致残的疾病。目前的治疗方法(镇痛药、非甾体抗炎药、COX-2 抑制剂、类固醇)不能延缓 OA 的进展或逆转关节损伤。此外,它们可能会引起相关的全身副作用。透明质酸(HA)是滑液的生理成分,在 OA 关节中减少。因此,关节内注射 HA 由于其粘弹性特性和对关节软骨和软组织表面的保护作用,可以恢复正常的关节内平衡。当 HA 正确地注入关节间隙时,这些效果是明显的;因此,必须使用“图像引导”渗透技术。当患者从其他治疗方法中未获得疼痛缓解或对镇痛药或 NSAIDs 不耐受时,可以考虑使用不同 HA 制剂(低和高分子量)的粘性补充剂(VS)。通常建议使用 3-5 剂量方案,每次注射之间间隔 1 周。几项研究表明,HA 治疗膝骨关节炎的疗效,对疼痛、关节功能(西安大略和麦克马斯特大学骨关节炎指数[WOMAC]、Lequesne 指数[LI]、关节活动度[ROM])、主观整体评估和 NSAIDs 消耗减少有积极影响。一般来说,在 3 个月内就能明显看到益处,并在接下来的 6-12 个月内持续存在。在治疗肩、腕掌、髋和踝骨关节炎方面也观察到了令人鼓舞但不确定的结果。然而,需要进行更好设计的研究来证明这些药物的有效性,以排除安慰剂效应。该疗法具有良好的耐受性,没有全身副作用,只有有限的局部不适。